

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Charles A. Simonton MD, FACC, FSCAI
Sanger Clinic
Medical Director
Clinical Innovation and Research
Carolinas Heart Institute
Charlotte, NC

TCT Asia Pacific
Seoul, Korea
April 2007

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

- I. Background**
- II. REPLACE-2 Outcomes**
- III. ADEST Registry: High Risk Subgroups**
- IV. STENT Registry: High Risk Subgroup—Bivalirudin
vs Heparin+GPIIbIIIa Agents**
- V. ACUTY PCI: High-Risk Subgroups**
- VI. CONCLUSIONS**


ACC/AHA Class I Recommendations for Antithrombotic Therapy*

Possible ACS	Likely/Definite ACS	Definite ACS With Invasive Strategy (Catheterization/PCI) or High Risk (IIa)*
Aspirin	Aspirin + SQ LMWH* or IV Heparin	Aspirin + IV Heparin + IV Platelet GP IIb/IIIa Antagonist
	Clopidogrel	Clopidogrel

* Class IIa: enoxaparin preferred over UFH unless CABG planned within 24 hours.

ACC, American College of Cardiology; AHA, American Heart association; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; SQ LMWH, subcutaneous low molecular-weight heparin; IV, intravenous.


Direct Thrombin Inhibitors or GP IIb/IIIa Agents Versus Heparin Alone: ACS Meta-analyses



DTI vs UFH (end of Rx)	DTI	UFH	OR
Death/MI	4.3%	5.1%	0.85
MI	5.0%	5.8%	0.80
Death	7.4%	8.2%	0.95

DTI vs UFH (30 days)	DTI	UFH	OR
Death/MI	1.9%	2.0%	0.92
MI	2.2%	2.3%	0.88
Death	3.6%	3.7%	0.99

DTI Collab Group. *Lancet* 2002;359:294-302




IIb/IIIa vs UFH (end of Rx)	IIb/IIIa	UFH	OR
Death/MI	5.7%	6.9%	0.84
MI	4.5%	5.6%	0.83
Death	1.2%	1.3%	0.93

IIb/IIIa vs UFH (30 days)	IIb/IIIa	UFH	OR
Death/MI	10.8%	11.8%	0.91
MI	7.4%	8.1%	0.92
Death	3.4%	3.7%	0.91


Boersma *Lancet* 2002;359:189-98 (NSTE-ACS patients only)

One-Year Mortality: ACS Subgroups




Lincoff AM et al. *JAMA*. 2004;292:696-703.
Stone GW. *J Invasive Cardiol*. 2004;16(suppl G):12-17.

One year mortality: Prior Heparin



REPLACE-2

1-Year Mortality: Subgroup Analysis



Odds ratio ±95% CI for death at 12 months

Bivalirudin and DES: ADEST Registry

Table 3
Major adverse events in patients with high-risk features

High-Risk Patient Subgroup	In-hospital Events	Out-of-hospital Events	Cumulative to 30 Days
Diabetes mellitus	(n = 359)	(n = 341)	(n = 341)
MACE	4.7%	2.9%	7.9%
Stent thrombosis	0.3%	0%	0.3%
Major bleeding	0.8%	NA	0.8%
Minor bleeding	3.3%	NA	3.3%
Multivessel PCI	(n = 206)	(n = 199)	(n = 199)
MACE	6.8%	1.5%	8.0%
Stent thrombosis	1%	0.5%	1.5%
Major bleeding	0%	NA	0%
Minor bleeding	6.3%	NA	6.3%
Multilesion PCI	(n = 469)	(n = 450)	(n = 450)
MACE	7.0%	2.0	8.9%
Stent thrombosis	0.4%	0.4%	0.9%
Major bleeding	0.6%	NA	0.6%
Minor bleeding	4.1%	NA	4.1%
Saphenous venous graft PCI	(n = 110)	(n = 103)	(n = 103)
MACE	6.4%	1.9%	8.7%
Stent thrombosis	1.8%	0%	1.8%
Major bleeding	0.9%	NA	0.9%
Minor bleeding	2.7%	NA	2.7%
Chronic renal insufficiency	(n = 70)	(n = 67)	(n = 67)
MACE	8.6%	3.0%	11.9%
Stent thrombosis	0%	0%	0%
Major bleeding	1.4%	NA	1.4%
Minor bleeding	4.3%	NA	4.3%

**Comparative Clinical Outcomes of Bivalirudin Versus
Heparin Plus GPIIb/IIIa Agents in **High-Risk**
Percutaneous Coronary Intervention (PCI): Results
from the Strategic Transcatheter Evaluation of New
Therapies (STENT) Group**

**John McPherson MD, Howard Walpole MD, Bruce
Brodie MD, Ian Smith MD, Barrett Cheek MD,
Bruce Brodie MD, James Hermiller MD, Christopher
Metzger MD, Sherry Laurent PhD,
Charles Simonton MD**

STENT Group Participating Centers:

Carolinas Heart Institute, Charlotte, NC

High Point Regional Hospital, High Point, NC

Holston Valley Medical Center, Kingsport, TN

Indiana Heart Institute, Indianapolis, IN

McLeod Regional Medical Center, Florence, SC

**LeBauer Cardiovascular Research Foundation /
Moses Cone Hospital, Greensboro, NC**

Sisters of Charity Providence Hospitals, Columbia, SC

STENT Group Data Coordinating Center:

R. Stuart Dickson Institute for Health Studies, Charlotte, NC

High Risk Patient-Level Characteristics Evaluated in Association with In-Hospital MACE (n=8107 procedures)

	W/O Factor <u>% MACE</u>	W/Factor <u>% MACE</u>	P-value
Age > 75	2.3	4.7	<0.0001
MI < 7 days	2.0	4.0	<0.0001
3 Vessel Disease	2.3	4.7	<0.0001
EF < 40	2.3	6.2	<0.0001
CHF (Hx or Acute)	2.4	5.7	<0.0001
Diabetes	2.8	2.5	0.4018
Hx of CABG	2.7	2.8	0.8999
Hx of MI	2.6	3.2	0.1451
Angina < 24 hours	2.7	3.2	0.4096

High Risk Lesion-Level Characteristics Evaluated in Association with In-Hospital MACE (n=8107 procedures)

	W/O Factor <u>% MACE</u>	W/Factor <u>% MACE</u>	P-value
Lesion > 20mm	2.2	4.8	<0.0001
Calcium	2.2	4.2	<0.0001
Thrombus Grade > 1	2.0	5.7	<0.0001
SVG	2.7	3.5	0.2257
Left Main	2.7	5.6	0.0900
Vessel Diameter <= 2.5mm	2.5	3.2	0.0729
Bifurcation	2.7	3.0	0.6472
Ostial	2.7	2.6	0.8596
CTO	2.7	2.6	0.9471

Volume of High Risk Procedures by Anti-Coagulation Therapy (n=8107 procedures)

	<u>Low Risk</u>	<u>High Risk</u>	<u>Total</u>
Bivalirudin Alone	243 (27%)	662 (73%)	905
GPIIbIIIa + Heparin	969 (21%)	3743 (79%)	4712
Other Therapy Groups	688 (28%)	1802 (72%)	2490
Total	1900 (23%)	6207 (77%)	8107

Adverse Outcomes: Definitions

BLEED-1

TIMI Major or TIMI Minor in-hospital

BLEED-2

TIMI Major or Decline in Hemoglobin ≥ 4 g/dL in hospital

MACE at 90 Days

Death, Myocardial Infarction, or Target Vessel Revascularization within 90 days of procedure

Unadjusted Associations with In-Hospital Bleeding Outcomes Comparing Bivalirudin Alone (BIV) to GPIIbIIIa + Heparin (GP/Hep) among High Risk Patients (n=4405)

	<u>BIV (n=662)</u>	<u>GP/Hep (n=3743)</u>	<u>P-value</u>
BLEED-1	16 (2.4%)	123 (3.3%)	0.2383
TIMI Major	6 (0.9%)	46 (1.2%)	0.4787
TIMI Minor	10 (1.5%)	77 (2.1%)	0.3515
BLEED-2	9 (1.4%)	178 (4.8%)	<0.0001
↓ Hg _≥ 4g/dL	7 (1.1%)	174 (4.7%)	<0.0001

Adjusted Associations with In-Hospital Bleeding Outcomes Comparing Bivalirudin Alone (BIV) to GPIIbIIIa + Heparin (GP/Hep) among High Risk Patients (n=4405)

	<u>Adjusted* OR (GP/Hep vs BIV)</u>	<u>95% CI</u>	<u>P-value</u>
BLEED -1	1.0	(0.6, 1.7)	0.9580
BLEED-2	2.7	(1.4, 5.3)	0.0057

***Additional factors in each model:**

Bleed-1 (mi<7 days, calcium, and thrombus grade>1)

Bleed-2 (age, mi<7days, and thrombus grade> 1)

**Unadjusted Associations with MACE at 90 days
Comparing Bivalirudin Alone (BIV) to GPIIbIIIa +
Heparin (GP/Hep) among High Risk Patients with
Completed 90 Day Follow-Up (n=3355)**

	<u>BIV (n=595)</u>	<u>GP/Hep (n=2760)</u>	<u>P-value</u>
MACE @ 90 Days	40 (6.7%)	170 (6.2%)	0.6069
Death	19 (3.2%)	82 (3.0%)	0.7735
MI	15 (2.5%)	62 (2.3%)	0.6849
TVR	13 (2.2%)	46 (1.7%)	0.3831

Adjusted Association with MACE at 90 Days Comparing Bivalirudin Alone (BIV) to GPIIbIIIa + Heparin (GP/Hep) among High Risk Patients (n=3355)

	<u>Adjusted* OR (GP/Hep vs BIV)</u>	<u>95% CI</u>	<u>P-value</u>
MACE @ 90 Days	0.9	(0.6, 1.3)	0.4437


*Additional factors in model:

age, mi<7days, chf, lesion length>20mm, and thrombus grade > 1

ACUITY PCI Sub-study

- Examine the outcomes of bivalirudin \pm GPIIb/IIIa inhibitors compared to heparin (unfractionated or enoxaparin) + GPIIb/IIIa inhibitors in pts with moderate and high risk ACS undergoing PCI
 - 3 primary clinical endpoints at 30 days
 - Angiographic outcomes from a large independent blinded core lab analysis
 - Specific subgroups and analyses of interest:
 - **Troponin positive pts**
 - **Impact of pre-PCI thienopyridine use**
 - **“ISAR-REACT-2 like” cohort**
 - **Angiographic thrombus**

ACUITY PCI: Management Strategy (N=13,819)



Heparin + IIb/IIIa

N = 2,561

Bivalirudin + IIb/IIIa


N = 2,609

Bivalirudin alone

N = 2,619

ACUITY PCI : Net Clinical Outcomes


Heparin + IIb/IIIa vs Bivalirudin + IIb/IIIa vs Bivalirudin Alone



*Heparin=unfractionated or enoxaparin

ACUITY PCI : Composite Ischemia


Heparin + IIb/IIIa vs Bivalirudin + IIb/IIIa vs Bivalirudin Alone




*Heparin=unfractionated or enoxaparin

ACUITY PCI : Adjudicated Stent Thrombosis

PCI Patients With ≥ 1 Stent Implanted (N=7,211)




ACUTY PCI : Impact of Baseline Troponins



Interaction P values = 0.46, 0.86 and 0.28 respectively

ACUITY PCI : Influence of Thienopyridines


30 Day Primary Endpoint Adverse Events



*Thienopyridine at any time, any dose, up to time of PCI

Interaction P values = 0.17, 0.19 and 0.65 respectively

ACUITY PCI: Thienopyridine Use and Relative Risk of Composite Ischemic Endpoint




Risk ratio $\pm 95\%$ CI for triple endpoint
(death, MI, unplanned revascularization)

*reflects patients in two study arms


“ISAR-REACT-2 Like” Patients (N=1,358)

*Troponin+ PCI pts, Thienopyridine use prior to PCI,
GPI started after angiography but before PCI*



ACUITY PCI: Thrombotic Lesions

Patients with ≥ 1 PCI Thrombotic Lesion at Baseline (n=712)



*Heparin=unfractionated or enoxaparin

Conclusions and Clinical Implications

- In patients with moderate and high risk ACS undergoing PCI
 - Replacing upstream heparin with bivalirudin in pts treated with GP IIb/IIIa inhibitors provides similar clinical and angiographic outcomes
 - Replacing heparin and GP IIb/IIIa inhibitors with bivalirudin alone (with provisional IIb/IIIa inhibitor use in <10% of pts) results in similar rates of ischemia with markedly reduced hemorrhagic complications, thereby improving overall event-free survival